Wei Sun1, Lianhai Zhang, Xiaojing Cheng, Xiaohong Wang, Xiaofang Xing, Hong Du, Jiafu Ji. 1. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Cancer Surgery, Peking University Cancer Hospital and Institute, Beijing 100142, China. jiafuj@hotmail.com.
Abstract
OBJECTIVE: To investigate the expression of serum endothelial cell specific molecule 1 (ESM-1) in gastric cancer and to evaluate the effect of serum ESM-1 as a potential serum biomarker. METHODS: Serum ESM-1 was detected by enzyme-linked immunosorbent assay (ELISA) and CEA, CA19.9, CA72.4 were detected by electrochemiluminescence immunoassay (ECLIA) in 102 patients with gastric cancer preoperatively. At the same time, serum ESM-1, CEA, CA19-9, CA72-4 in 41 healthy adults volunteers were detected with the same method. In addition, the follow-up data of all the patients were collected. RESULTS: Compared to healthy volunteers, the serum ESM-1 level in gastric cancer patients increased (P<0.01). The sensitivity and specificity of serum ESM-1 were 73.9% and 51.2% respectively. In contrast, the sensitivities of CEA, CA19-9 and CA72-4 were only 16.1%, 18.3% and 23.2% respectively. High level of serum ESM-1 indicated poor outcomes (P<0.05). CONCLUSIONS: Serum ESM-1 increases in the peripheral blood of the gastric cancer patients. It may be a potential serum marker to help diagnosis and prediction of prognosis of gastric cancer patients.
OBJECTIVE: To investigate the expression of serum endothelial cell specific molecule 1 (ESM-1) in gastric cancer and to evaluate the effect of serum ESM-1 as a potential serum biomarker. METHODS: Serum ESM-1 was detected by enzyme-linked immunosorbent assay (ELISA) and CEA, CA19.9, CA72.4 were detected by electrochemiluminescence immunoassay (ECLIA) in 102 patients with gastric cancer preoperatively. At the same time, serum ESM-1, CEA, CA19-9, CA72-4 in 41 healthy adults volunteers were detected with the same method. In addition, the follow-up data of all the patients were collected. RESULTS: Compared to healthy volunteers, the serum ESM-1 level in gastric cancerpatients increased (P<0.01). The sensitivity and specificity of serum ESM-1 were 73.9% and 51.2% respectively. In contrast, the sensitivities of CEA, CA19-9 and CA72-4 were only 16.1%, 18.3% and 23.2% respectively. High level of serum ESM-1 indicated poor outcomes (P<0.05). CONCLUSIONS: Serum ESM-1 increases in the peripheral blood of the gastric cancerpatients. It may be a potential serum marker to help diagnosis and prediction of prognosis of gastric cancerpatients.